148 related articles for article (PubMed ID: 27164485)
1. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period.
Villas-Boas J; Vilodre LC; Malerba H; Pontremoli Salcedo M; Foresti Jiménez M; El Beitune P
Eur J Obstet Gynecol Reprod Biol; 2016 Jul; 202():51-4. PubMed ID: 27164485
[TBL] [Abstract][Full Text] [Related]
2. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
Bender NM; Segall-Gutierrez P; Najera SO; Stanczyk FZ; Montoro M; Mishell DR
Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
[TBL] [Abstract][Full Text] [Related]
3. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study.
Brito MB; Ferriani RA; Quintana SM; Yazlle ME; Silva de Sá MF; Vieira CS
Contraception; 2009 Dec; 80(6):519-26. PubMed ID: 19913145
[TBL] [Abstract][Full Text] [Related]
4. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population.
Di Carlo C; Guida M; De Rosa N; Sansone A; Gargano V; Cagnacci A; Nappi C
Gynecol Endocrinol; 2015 Jun; 31(6):491-4. PubMed ID: 26213863
[TBL] [Abstract][Full Text] [Related]
5. Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study.
Oderich CL; Wender MC; Lubianca JN; Santos LM; de Mello GC
Contraception; 2012 Feb; 85(2):173-6. PubMed ID: 22067787
[TBL] [Abstract][Full Text] [Related]
6. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
[TBL] [Abstract][Full Text] [Related]
7. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
[TBL] [Abstract][Full Text] [Related]
8. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
Romano ME; Braun-Courville DK
J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
[TBL] [Abstract][Full Text] [Related]
9. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels.
Dilbaz B; Ozdegirmenci O; Caliskan E; Dilbaz S; Haberal A
Contraception; 2010 Jun; 81(6):510-4. PubMed ID: 20472118
[TBL] [Abstract][Full Text] [Related]
10. Etonogestrel implant in women with diabetes mellitus.
Vicente L; Mendonça D; Dingle M; Duarte R; Boavida JM
Eur J Contracept Reprod Health Care; 2008 Dec; 13(4):387-95. PubMed ID: 19117254
[TBL] [Abstract][Full Text] [Related]
11. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial.
Hou MY; McNicholas C; Creinin MD
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):361-6. PubMed ID: 27419258
[TBL] [Abstract][Full Text] [Related]
12. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Davis A; Swartz M; Guiahi M
Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
[TBL] [Abstract][Full Text] [Related]
13. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
[TBL] [Abstract][Full Text] [Related]
14. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation.
Wilson S; Tennant C; Sammel MD; Schreiber C
Contraception; 2014 Sep; 90(3):259-64. PubMed ID: 24993485
[TBL] [Abstract][Full Text] [Related]
15. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of contraceptive implants in adolescents.
Guazzelli CA; de Queiroz FT; Barbieri M; Barreiros FA; Torloni MR; Araujo FF
Contraception; 2011 Oct; 84(4):409-12. PubMed ID: 21920197
[TBL] [Abstract][Full Text] [Related]
17. Etonogestrel-Releasing Contraceptive Implant for Postpartum Adolescents: A Randomized Controlled Trial.
Bryant AG; Bauer AE; Stuart GS; Levi EE; Zerden ML; Danvers A; Garrett JM
J Pediatr Adolesc Gynecol; 2017 Jun; 30(3):389-394. PubMed ID: 27561981
[TBL] [Abstract][Full Text] [Related]
18. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up).
Inal MM; Yildirim Y; Ertopcu K; Avci ME; Ozelmas I; Tinar S
Eur J Contracept Reprod Health Care; 2008 Sep; 13(3):238-42. PubMed ID: 18609340
[TBL] [Abstract][Full Text] [Related]
19. One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement.
Mark A; Sonalkar S; Borgatta L
Contraception; 2013 Nov; 88(5):619-23. PubMed ID: 23790436
[TBL] [Abstract][Full Text] [Related]
20. Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting.
Riney S; O'Shea B; Forde A
Ir Med J; 2009 Jan; 102(1):24-5. PubMed ID: 19284015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
